The Technical Analyst
Repare Therapeutics Inc. [RPTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Repare Therapeutics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-5.92% $3.02
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 127.39 mill |
| EPS: | -2.23 |
| P/E: | -1.350 |
| Earnings Date: | Feb 26, 2024 |
| SharesOutstanding: | 42.18 mill |
| Avg Daily Volume: | 0.128 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.350 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.23x |
| Company: PE -1.350 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.56 - 3.46 ( +/- 15.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-28 | Segal Lloyd Mitchell | Sell | 2 650 | Common Shares |
| 2024-04-01 | Segal Lloyd Mitchell | Sell | 2 491 | Common Shares |
| 2024-03-28 | Forte Steve | Sell | 825 | Common Shares |
| 2024-04-01 | Forte Steve | Sell | 789 | Common Shares |
| 2024-03-28 | Zinda Michael | Sell | 450 | Common Shares |
| INSIDER POWER |
|---|
| 67.33 |
| Last 99 transactions |
| Buy: 4 214 315 | Sell: 3 499 776 |
Forecast:
16:00 - $3.00
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.00
Forecast 2: 16:00 - $3.00
Forecast 3: 16:00 - $3.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.02 (-5.92% ) |
| Volume | 0.139 mill |
| Avg. Vol. | 0.128 mill |
| % of Avg. Vol | 108.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RPTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:30 | sell | $7.98 | N/A | Active |
|---|
RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Latest Press Releases
2024-03-21 10:00:00 - Press Release
Repare Therapeutics Inc. (rptx) Investigation: Bronstein, Gewirtz & Grossman, Llc Encourages Investors To Seek Compensation For Alleged Wrongdoings
New york--(business wire)---- $rptx #classaction--attorney advertising--bronstein, gewirtz & grossman, llc is investigating potential claims on behalf of purchasers of repare therapeutics inc. (“repare” or “the company”) (nasdaq: rptx). investors who purchased repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/rptx. investigation details: on february 12, 2024, repare issued a press release “announc[ing] . . . that it will regain g.
2024-03-15 14:35:00 - Press Release
Repare Therapeutics Inc. (rptx) Investigation: Bronstein, Gewirtz & Grossman, Llc Encourages Investors To Seek Compensation For Alleged Wrongdoings
New york--(business wire)---- $rptx #classaction--attorney advertising--bronstein, gewirtz & grossman, llc is investigating potential claims on behalf of purchasers of repare therapeutics inc. (“repare” or “the company”) (nasdaq: rptx). investors who purchased repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/rptx. investigation details: on february 12, 2024, repare issued a press release “announc[ing] . . . that it will regain g.
2024-03-11 20:00:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repare Therapeutics Inc. - Rptx
New york, march 11, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of repare therapeutics inc. ("repare" or the "company") (nasdaq: rptx). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-03-05 12:15:00 - Press Release
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky To Discuss Your Rights - Rptx
New york, ny / accesswire / march 5, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of repare therapeutics inc. ("repare therapeutics") (nasdaq:rptx) concerning possible violations of federal securities laws. repare therapeutics issued a press release, on february 12, 2024, "announc[ing].
2024-03-03 10:15:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repare Therapeutics Inc. - Rptx
New york , march 3, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of repare therapeutics inc. ("repare" or the "company") (nasdaq: rptx). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
Latest News
2024-02-29 07:05:00 - Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming investor conferences. Details for the presentations are as follows. TD Cowen 44th Annual Healthcare Conference Panel Discussion: Gynecological Cancers Date: Tuesday, March 5, 2024 Time: 10:30 a.m. Eastern Time Location: Boston, MA Bloom Bu.
2024-02-20 11:06:55 - Zacks Investment Research
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Repare Therapeutics Inc. (RPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-13 05:46:04 - Zacks Investment Research
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
2023-11-20 09:46:16 - Zacks Investment Research
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.
2023-11-06 19:43:49 - Seeking Alpha
Repare: Potential Of Camonsertib With Several Shots On Goal
Repare Therapeutics presented preliminary results from the phase 1 MYTHIC study using the lunresertib and camonsertib combination for the treatment of patients with multiple solid tumor types. The biotech plans to complete the phase 1 expansion portion of the phase 1 MYTHIC study and release results in 2024. Plus, potentially initiating late-stage trials in 2024 thereafter. Highly impressive data from the lunresertib and camonsertib combination was observed in patients with gynecological tumors, where the OR was 60%.
2023-10-11 11:19:33 - Zacks Investment Research
Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround
Repare Therapeutics Inc. (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-10-09 11:17:53 - Zacks Investment Research
Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 Weeks
The heavy selling pressure might have exhausted for Repare Therapeutics Inc. (RPTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-10-03 07:00:00 - Business Wire
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to share initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial that will be presented in a plenary session at the upcoming AACR-NCI-EORTC conference, being held October 11-15, 2023 in Boston, MA. The data that will be presented at AACR-NCI-EOR.
2023-09-20 06:01:07 - Zacks Investment Research
Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2023-08-16 14:54:00 - The Motley Fool
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
Cathie Wood's ARK Genomic Revolution ETF is a top shareholder of Repare Therapeutics. Wood, along with several Wall Street analysts, hold an overtly bullish view on the biotech's growth prospects.